Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/ PPARγ/PTEN/mTOR signaling pathway

Thirty to 40 % of non-small cell lung cancer (NSCLC) patients developed higher hypertriglyceridemia in the process of treatment with bexarotene. And bioinformatics studies discovered that the expression of slc10a2 was increased in high-grade hypertriglyceridemia patients.